Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page
- Check5 days agoChange DetectedRevision indicator on the page was updated to v3.6.6, replacing the previous v3.6.5.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe revision label was updated from v3.6.4 to v3.6.5, indicating a platform update. The study details and user-facing content remain unchanged.SummaryDifference0.1%

- Check40 days agoChange DetectedThe page shows a new revision label, updating from v3.6.3 to v3.6.4, indicating a deployment of a new build. The underlying study information and content remain unchanged.SummaryDifference0.1%

- Check62 days agoChange DetectedThe revision label in the page footer was updated from v3.6.2 to v3.6.3, signaling a minor maintenance update to the site.SummaryDifference0.1%

- Check69 days agoChange DetectedPage footer revision label updated from v3.6.0 to v3.6.2, indicating a minor platform update to the study details page. This change does not affect the study content or data displayed on the page.SummaryDifference0.1%

- Check83 days agoChange DetectedThe page adds recruitment status information and new guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) while standardizing the Intervention/Treatment label and updating the revision tag to v3.6.0.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.